More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$637317091
EPS
-3.46
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
-0.338487
Previous close
$9.75
Today's open
$9.83
Day's range
$9.34 - $9.92
52 week range
$7.87 - $30.99
show more
CEO
Claire Mazumdar
Employees
103
Headquarters
Boston, MA
Exchange
NASDAQ Global Market
Shares outstanding
66387197
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call
Bicara Therapeutics NASDAQ: BCAX said its pivotal study of FICERA in a form of advanced head and neck cancer has reached sufficient enrollment to support a planned top-line interim analysis in mid-2027.
MarketBeat • Nov 9, 2026

Bicara Therapeutics Inc. (BCAX) Q3 2026 Earnings Call Transcript
Bicara Therapeutics Inc. (BCAX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 9, 2026

Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027 Enrolling FORTIFI-FLEX alternate dosing study; expect to have data by the time of potential U.S. approval in 1L R/M HPV-negative HNSCC Company to host conference call and webcast today, November 9, 2026 at 8:30 a.m. ET BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the third quarter ended September 30, 2026 and provided a business update.
GlobeNewsWire • Nov 9, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on November 2, 2026, to one new employee as a material inducement to employment under Bicara's 2026 Inducement Plan.
GlobeNewsWire • Nov 4, 2026

Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report third quarter 2026 financial results and business updates before the market opens on Monday, November 9, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.
GlobeNewsWire • Nov 2, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on October 1, 2026 to two new employees as a material inducement to employment under Bicara's 2026 Inducement Plan.
GlobeNewsWire • Oct 5, 2026

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara's 2026 Inducement Plan as a material inducement to her commencement of employment as Bicara's Chief Financial Officer. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $24.63 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on August 12, 2026.
GlobeNewsWire • Aug 14, 2026

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.
Benzinga • Aug 12, 2026

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but toxicity and small cohort size warrant caution ahead of pivotal phase 3 readout. Strong cash position ($500M liquidity) supports operations into 2029, enabling pursuit of interim phase 3 results and potential commercialization.
Seeking Alpha • Aug 12, 2026

Bicara Therapeutics Q2 Earnings Call Highlights
Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of ficerafusp alfa, or FICERA, while reaffirming its cash runway into the first half of 2029.
MarketBeat • Aug 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Bicara Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.